276 related articles for article (PubMed ID: 16177881)
21. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
[TBL] [Abstract][Full Text] [Related]
22. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance.
Yu JX; Zhang XT; Liao YQ; Zhang QY; Chen H; Lin M; Kumar S
World J Gastroenterol; 2003 Dec; 9(12):2866-9. PubMed ID: 14669355
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
[TBL] [Abstract][Full Text] [Related]
24. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
[TBL] [Abstract][Full Text] [Related]
25. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
[TBL] [Abstract][Full Text] [Related]
26. The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis.
Jung I; Gurzu S; Raica M; Cîmpean AM; Szentirmay Z
Rom J Morphol Embryol; 2009; 50(2):239-43. PubMed ID: 19434317
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
[TBL] [Abstract][Full Text] [Related]
28. Assessment of vascularity as an index of angiogenesis in periradicular granulomas. Comparison with oral carcinomas and normal tissue counterparts.
Davey KJ; Perrier S; Ohe G; Gilbert AD; Bankfalvi A; Saunders WP; Schor SL; Schor AM
Int Endod J; 2008 Nov; 41(11):987-96. PubMed ID: 19133088
[TBL] [Abstract][Full Text] [Related]
29. Expression of endoglin (CD105) in cervical cancer.
Zijlmans HJ; Fleuren GJ; Hazelbag S; Sier CF; Dreef EJ; Kenter GG; Gorter A
Br J Cancer; 2009 May; 100(10):1617-26. PubMed ID: 19352388
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions.
Ding S; Li C; Lin S; Yang Y; Liu D; Han Y; Zhang Y; Li L; Zhou L; Kumar S
Hum Pathol; 2006 Jul; 37(7):861-6. PubMed ID: 16784986
[TBL] [Abstract][Full Text] [Related]
31. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
33. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
34. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.
Safwat MD; Habib F; Elayat A; Oweiss N; Reffat S; Algaidi S
Folia Morphol (Warsz); 2009 Aug; 68(3):144-55. PubMed ID: 19722158
[TBL] [Abstract][Full Text] [Related]
35. Endoglin (CD105) expression in endometrial carcinoma.
Saad RS; Jasnosz KM; Tung MY; Silverman JF
Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
[TBL] [Abstract][Full Text] [Related]
36. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression.
Marioni G; Giacomelli L; D'Alessandro E; Staffieri C; Guzzardo V; Staffieri A; Blandamura S
Anticancer Res; 2008; 28(1B):551-7. PubMed ID: 18383901
[TBL] [Abstract][Full Text] [Related]
37. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays.
Charpin C; Dales JP; Garcia S; Carpentier S; Djemli A; Andrac L; Lavaut MN; Allasia C; Bonnier P
Clin Cancer Res; 2004 Sep; 10(17):5815-9. PubMed ID: 15355911
[TBL] [Abstract][Full Text] [Related]
38. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
39. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival.
Sugita Y; Takase Y; Mori D; Tokunaga O; Nakashima A; Shigemori M
J Neurooncol; 2007 May; 82(3):249-56. PubMed ID: 17102906
[TBL] [Abstract][Full Text] [Related]
40. Endoglin (CD105) expression and angiogenesis status in small cell lung cancer.
Takase Y; Kai K; Masuda M; Akashi M; Tokunaga O
Pathol Res Pract; 2010 Nov; 206(11):725-30. PubMed ID: 20619547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
